Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Ahead of its July 15 report, investors are likely to focus on the same set of questions that have historically driven how the market values Johnson & Johnson: operating momentum across its healthcare businesses, cash generation, and how management frames risks and forward demand.
THE APEX TIMES
THE APEX TIMES
A fresh market commentary argues the GLP-1 leaders remain well positioned, but says there are also opportunity sets outside the two blockbuster drug makers.
THE APEX TIMES
The transfer of full mainland commercialization control of Verzenios to Innovent Biologics is reshaping expectations for Eli Lilly’s role in China oncology, while also adding to questions about valuation and regulatory exposure.
THE APEX TIMES
Eli Lilly shares rose about 2.8% in the afternoon after JPMorgan’s Chris Schott raised his price target to $1,400 from $1,300 and reiterated an Overweight rating, pointing to sustained demand for its weight-loss drugs and an expanded incretin pipeline.
THE APEX TIMES
The insurer commissioned FTI Consulting to review diagnosis coding tied to its HouseCalls in-home visits for Medicare Advantage members after scrutiny over whether diagnoses were being overstated for higher payments.
THE APEX TIMES
Eli Lilly was among the day’s notable gainers even as the Nasdaq moved lower, with weakness also hitting memory and semiconductor equipment names such as Sandisk and Micron, according to market coverage published July 7, 2026.
THE APEX TIMES
Construction at the former Pfizer global headquarters on Manhattan’s East 42nd Street was paused Tuesday after officials said the high-rise remained structurally unstable, triggering evacuations and renewed engineering scrutiny.
THE APEX TIMES
A new market roundup argues that some healthcare names offer steadier dividend characteristics than Pfizer, even as Pfizer is framed as the highest yielding stock in the S&P 500 after Conagra’s index demotion.
THE APEX TIMES
A new set of IMAAVY results discussed at the European Academy of Neurology congress is prompting fresh valuation talk around Johnson & Johnson’s JNJ stock, according to a market write-up published Tuesday.
